Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Healthcare: Should You Stick With Gilead Sciences?

  • Broadcast in Finance
Industry Focus

Industry Focus

Featured Host
×  

Follow This Show

If you liked this show, you should follow Industry Focus.
h:899941
s:10819795
archived
Play
  • Host

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled